{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-092039","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2026-08-06T20:19:09+00:00","discovered_at":"2026-08-06T20:20:01.347003+00:00","generated_at":"2026-08-06T20:20:47.729853+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytoSorbents Q2 2026 revenue flat at $9.6M; operating loss improves 27%","bullets":["Revenue $9.6M (unchanged YoY); gross margin 73% (up from 71% YoY).","Operating loss improved 27% to $2.6M; net loss $4.4M ($0.07) vs net income $1.9M ($0.03) in Q2 2025 due to FX.","Adjusted net loss improved 22% to $2.8M ($0.05); adjusted EBITDA loss improved 38% to $1.6M.","Cash burn reduced to $0.4M (incl. $0.2M restructuring); workforce cut 23% since Sep 2025.","Two FDA pre-submission meetings in Aug 2026 for DrugSorb-ATR (Brilinta and DOAC programs)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-092039","json":"https://secwatch.observer/filing/0001104659-26-092039.json","markdown":"https://secwatch.observer/filing/0001104659-26-092039.md","text":"https://secwatch.observer/filing/0001104659-26-092039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926092039/0001104659-26-092039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926092039/tm2622246d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:20:47.729853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}